Notícias e Atualizações de Tenaya

Tenaya Therapeutics Appoints Eric Hyllengren as Chief Financial Officer

Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to d...

Jun 29, 2026 • Markets Insider

H.C. Wainwright maintains buy rating on Tenaya Therapeutics stock

On Tuesday, H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on Tenaya Therapeutics ...

Jul 06, 2026 • Investing.com on MSN

Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac ...

All Evaluable Patients Achieved Improvements in Multiple Hallmarks of MYBPC3-Associated HCM Benefits...

Jun 03, 2026 • Markets Insider

Staying at Tenaya Lodge near Yosemite NP [An honest review | 2026 update]

There’s something about Yosemite – the pine-scented air, the granite giants, and the tumbling wa...

Jun 16, 2026 • Y Travel Blog on MSN

Tenaya Therapeutics to Present Preclinical Data on Gene Therapy Programs and Platform Capabilities at the American Society of Gene and Cell Therapy 25th Annual Meeting

ASGCT Presentations Include Preclinical Data for TN-401 PKP2 and DWORF Gene Therapy Programs and AAV...

May 03, 2022 • Nasdaq

Tenaya Therapeutics Announces Proposed Public Offering

SOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TN...

Dec 10, 2025 • Yahoo Finance

Tenaya Names Eric Hyllengren as CFO

Hyllengren has more than two decades of experience in biotechnology finance, capital markets and cor...

Jun 29, 2026 • MarketWatch

Tenaya Therapeutics Announces the Addition of Dr. June Lee to its Board of Directors

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a biotechnol...

Nov 21, 2021 • Nasdaq

Tenaya Therapeutics Presents Encouraging New Clinical and Preclinical Data from HDAC6 Inhibitor Program TN-301 for the Potential Treatment of Heart Failure with Preserved ...

SOUTH SAN FRANCISCO, Calif. and CLEVELAND, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, In...

Oct 08, 2023 • Yahoo Finance

Tenaya Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

One-Year Cohort 1 Data and Initial Cohort 2 Data from RIDGE™-1 Phase 1b/2 Trial of TN-401 for PKP2...

May 06, 2026 • manilatimes

Tenaya Therapeutics to Present Preclinical Data on TN-401 PKP2 Gene Therapy Program at Heart Rhythm 2022

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a biotechnol...

Apr 28, 2022 • Business Wire

Tenaya Therapeutics to Highlight Growing Capabilities in Capsid Engineering, Gene Editing and Manufacturing at the American Society of Gene and Cell Therapy 27th Annual Meeting

SOUTH SAN FRANCISCO, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNY...

May 01, 2024 • Yahoo Finance

Tenaya Therapeutics Announces Late-Breaking Oral Presentation of New Clinical Data from RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy in Adults with PKP2 ...

Readout to Include One-Year Cohort 1 Results and Early Cohort 2 Data; Webcast Conference Call Planne...

Apr 26, 2026 • manilatimes

Tenaya Therapeutics to Present Preclinical Data on TN-301 HDAC6 Inhibitor at European Society of Cardiology Heart Failure 2022 Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a biotechnol...

May 20, 2022 • Business Wire

Tenaya Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNY...

May 13, 2024 • Yahoo Finance

Tenaya Therapeutics Publishes Preclinical Data Demonstrating TN-201 Enhances Cardiac Function and Survival in MYBPC3 Cardiomyopathy Models

Robust Evidence of Disease Reversal in Severe Knock Out Mice Model Supports Tenaya’s Clinical Deve...

Mar 24, 2025 • Taiwan News

Tenaya Therapeutics to Present Five Abstracts on Innovative Heart Disease Gene Therapies at ASGCT 2025 Annual Meeting

Tenaya Therapeutics, Inc. announced that it will present five abstracts at the American Society of G...

May 13, 2025 • Nasdaq

Tenaya Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Enrollment Complete in Cohorts 1 and 2 of MyPEAK™-1 Phase 1b/2 Trial of TN-201 for MYBPC3-associat...

Aug 06, 2025 • Taiwan News

Tenaya Receives Positive Safety Reviews from Independent DSMBs to Advance Both TN-201 and TN-401 Gene Therapy Clinical Trials as Designed

Enrollment in Both Dose Cohorts of the MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Hypertrop...

Jul 29, 2025 • Morningstar

Tenaya Highlights Growing Capabilities in AAV Manufacturing, Capsid Engineering and Expansion into Gene Editing with Six Abstracts Accepted for Presentation at the ASGCT 26th ...

SOUTH SAN FRANCISCO, Calif., May 03, 2023 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNY...

May 02, 2023 • Yahoo Finance

Tenaya Capital Closes ‘Oversubscribed’ $372M Fund, Seeks A New Kayak

Tenaya Capital, the venture fund spun out of Lehman Brothers in 2009 with a history of backing compa...

Jul 24, 2012 • TechCrunch

Tenaya Therapeutics Reports Promising Early Data from MyPEAK(TM)-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy

SOUTH SAN FRANCISCO, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TN...

Jun 22, 2026 • Stockhouse

Tenaya Therapeutics Announces 2026 Strategic Priorities and Anticipated Milestones

Longer-Term Follow-Up Data for Cohorts 1 and 2 from MyPEAK™-1 Trial of Adults with MYBPC3-Associat...

Jun 19, 2026 • The Globe and Mail

Tenaya Therapeutics Announces Research Leadership Updates

SOUTH SAN FRANCISCO, Calif., June 27, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TN...

Jun 23, 2026 • Stockhouse

Tenaya Therapeutics Announces Pricing of Public Offering

SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: T...

Mar 03, 2025 • Yahoo Finance

Tenaya Therapeutics (TNYA) Is Up 26.6% After TN-401 Data Buzz and Narrower Losses Has The Bull Case Changed?

Tenaya Therapeutics recently reported a reduced net loss of US$19.27 million for the first quarter o...

May 11, 2026 • Yahoo Finance

Alnylam’s research pact worth up to $1.1B sends Tenaya higher

Tenaya Therapeutics (TNYA) added ~10% in the premarket on Thursday after the company signed a resear...

Mar 05, 2026 • Seeking Alpha

Tenaya Therapeutics to Announce New Interim Data from MyPEAK™-1 Phase 1b/2 Trial of TN-201 for Adults with MYBPC3-Associated HCM on Wednesday, June 3, 2026

SOUTH SAN FRANCISCO, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TN...

Jun 01, 2026 • Yahoo Finance

Tenaya, Alnylam in Cardiovascular Disease Research Collaboration Worth Up to $1.14B

Tenaya Therapeutics and Alnylam Pharmaceuticals are collaborating on research to find treatments for...

Mar 05, 2026 • MarketWatch

Tenaya Therapeutics Announces FDA Clearance of Investigational New Drug Application and Initiation of Phase 1 Safety Study for TN-301, an HDAC6 Inhibitor for Heart Failure with ...

SOUTH SAN FRANCISCO, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: T...

Sep 05, 2022 • Yahoo Finance